Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5α- reductase during prostate cancer progression

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1355-1358

  Akalu, Abebe ^b   Elmajian, Donald A ^b   Highshaw, Ralph A ^b   Nichols, Peter W ^b   Reichardt, Juergen K V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

Androgen metabolism; Genomic instability; Loss of heterozygosity

Indexed keywords

ANDROGEN; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ANDROGEN METABOLISM; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DINUCLEOTIDE REPEAT; GENE LOCUS; GENE MUTATION; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION;

EID: 0032862564     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61683-5     Document Type: Article

References (20)

1. Landis, S. H. and Murray, T.: Cancer statistics, 1998. CA: Cancer J. Clin., 48: 6, 1998.
2. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer. Cancer Res., 1: 293, 1941.
3. Coffey, D. S.: The molecular biology of the prostate. In: Prostate Diseases. Edited by H. Lepor and R. K. Lawson. W. B. Saunders: Philadelphia, pp. 28-56, 1993.
4. Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato-McGinley, J., Griffin, J. E., Francke, A., Wilson, J. D. and Russell, D. W.: Molecular genetics of steroid 5α-reductase 2 deficiency. J. Clin. Invest., 90: 799, 1992.
5. Davis, D. L. and Russell, D. W.: Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum. Molec. Gen., 2: 820, 1993.
6. Reichardt, J. K. V., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C. and Ross, R. K: Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973, 1995.
7. Silver, R. I., Wiley, E. L., Davis, D. L., Thigpen, A. E., Russell, D. W. and McConnell, J. D.: Expression and regulation of steroid 5α-reductase 2 in prostate disease. J. Urol., 152: 433, 1994.
8. Zhuang, Z., Bertheau, P., Emmert-Buck, M. R., Liotta, L. A., Gnarra, J., Linehan, W. M. and Lubensky, I. A.: A microdissection technique for archival DNA analysis of specific cell populations in lesions<1 mm in size. Am. J. Pathol., 146: 620, 1995.
9. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K.: Current Protocols in Molecular Biology, Wiley & Sons: New York, 1995.
10. Habib, F. K., Busuttil, A., Robinson, R. A. and Chisholm, G. D.: 5α-Reductase activity in human prostate cancer is related to the histological differentiation of the tumor. Clin. Endocrinol., 23: 431, 1985.
11. Montie, J. E. and Pienta, K. J.: Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology, 43: 892, 1994.
12. Sandberg, A. A.: Chromosome abnormalities and related events in prostate cancer. Hum. Path., 23: 368, 1992.
13. Cavenee, W. K.: Mitotic abnormalities leading to cancer predisposition and progression. Cancer Detec. Prev., 14: 269, 1989.
14. Cunningham, J. M.: Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res., 56: 4475, 1996.
15. Suzuki, H.: Microsatellite instability and other molecular abnormalities in human prostate cancer. Japan J. Cancer Res., 86: 956, 1995.
16. Dahiya, R.: High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int. J. Cancer, 72: 762, 1997.
17. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Maculaso, M.: The TNM classification of prostate cancer. Prostate, 4: 129,1992.
18. Gleason, D. F.: Histologic grading of prostate cancer. Hum. Pathol., 23: 273, 1992.
19. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C-Y., Yu, M. C., Henderson, B. E. and Reichardt, J. K. V.: A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020, 1997.
20. EpiInfo, Centers for Disease Control and Prevention, Version 6.:03, Atlanta, GA, July 1995.